<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03359837</url>
  </required_header>
  <id_info>
    <org_study_id>LANTUL07194</org_study_id>
    <secondary_id>U1111-1186-3400</secondary_id>
    <nct_id>NCT03359837</nct_id>
  </id_info>
  <brief_title>Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy</brief_title>
  <acronym>SWITCH</acronym>
  <official_title>A 26-Week, Multi-Center, Open-label, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-Term Intensive Insulin Therapy: Basal Insulin Based Treatment (With Prandial OADs Combination) Versus Twice-daily Premixed Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To test the hypothesis that basal insulin based treatment (G+) is noninferior to twice-daily&#xD;
      premixed insulin (PM-2) in term of hemoglobin A1c (glycosylated hemoglobin, HbA1c) reduction&#xD;
      from baseline to end of study. The test for superiority can be done if noninferiority is&#xD;
      achieved.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess efficacy in terms of percentage of patients achieving HbA1c &lt;7% and HbA1c &lt;7%&#xD;
           without hypoglycemia.&#xD;
&#xD;
        -  To assess efficacy in terms of percentage of patients achieving fasting plasma glucose&#xD;
           (FPG) &lt;7 mmol/L and FPG &lt;7 mmol/L without hypoglycemia.&#xD;
&#xD;
        -  To assess safety in term of occurrence of moderate/severe hypoglycemia.&#xD;
&#xD;
        -  To assess daily blood glucose (BG) variation.&#xD;
&#xD;
        -  To assess patient satisfaction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of study is approximately 21 months. Each patient will be followed for&#xD;
      approximately 27 weeks from screening visit to end-of-study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2018</start_date>
  <completion_date type="Actual">June 29, 2020</completion_date>
  <primary_completion_date type="Actual">June 29, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change in HbA1c from baseline to week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients with fasting plasma glucose (FPG) &lt;6.1 mmol/L</measure>
    <time_frame>At Week 12 and Week 24</time_frame>
    <description>Percentage of patients with FPG &lt;6.1 mmol/L at week 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with FPG &lt;6.1 mmol/L without hypoglycemia</measure>
    <time_frame>At Week 12 and Week 24</time_frame>
    <description>Percentage of patients with FPG &lt;6.1 mmol/L without hypoglycemia at week 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with FPG &lt;7 mmol/L</measure>
    <time_frame>At Week 12 and Week 24</time_frame>
    <description>Percentage of patients with FPG &lt;7 mmol/L at week 12 and week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with FPG &lt;7 mmol/L without hypoglycemia</measure>
    <time_frame>At Week 12 and Week 24</time_frame>
    <description>Percentage of patients with FPG &lt;7 mmol/L without hypoglycemia at week 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with HbA1c &lt;7%</measure>
    <time_frame>At Week 12 and Week 24</time_frame>
    <description>Percentage of patients with HbA1c &lt;7% at week 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with HbA1c &lt;7% without hypoglycemia</measure>
    <time_frame>At Week 12 and Week 24</time_frame>
    <description>Percentage of patients with HbA1c &lt;7% without hypoglycemia at week 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic events</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Incidence of hypoglycemia during treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change in FPG from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change in body weight from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dose</measure>
    <time_frame>At Week 24</time_frame>
    <description>Total daily insulin dose at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily BG variation at week 24</measure>
    <time_frame>At Week 24</time_frame>
    <description>Daily blood glucose (BG) variation at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European quality of life - 5 dimensions (EQ-5D)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change in quality of life scores from baseline to week 24 on 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is measured at 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problem.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis</measure>
    <time_frame>At week 24</time_frame>
    <description>Subgroup analysis of control rate of HbA1c &lt;7% according to duration of diabetes, oral anti-hyperglycemic drug(OAD) treatment and HbA1c at screening, FPG, post prandial glucose(PPG) excursion and C peptide at the beginning of run-in period, insulin dose at end of run-in period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">384</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Glargine based therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily glargine plus prandial oral anti-hyperglycemic drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Premixed insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twice daily premixed insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE (HOE901)</intervention_name>
    <description>Pharmaceutical form: solution for injection&#xD;
Route of administration: subcutaneous injection</description>
    <arm_group_label>Glargine based therapy</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glulisine</intervention_name>
    <description>Pharmaceutical form: solution for injection&#xD;
Route of administration: subcutaneous injection</description>
    <arm_group_label>Glargine based therapy</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biphasic insulin aspart 30</intervention_name>
    <description>Pharmaceutical form: solution for injection&#xD;
Route of administration: subcutaneous injection</description>
    <arm_group_label>Premixed insulin</arm_group_label>
    <other_name>Novolog Mix70/30</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repaglinide</intervention_name>
    <description>Pharmaceutical form: tablet&#xD;
Route of administration: oral administration</description>
    <arm_group_label>Glargine based therapy</arm_group_label>
    <other_name>NovoNorm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>Pharmaceutical form: tablet&#xD;
Route of administration: oral administration</description>
    <arm_group_label>Glargine based therapy</arm_group_label>
    <other_name>Glucobay</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Pharmaceutical form: tablet or capsule&#xD;
Route of administration: oral administration</description>
    <arm_group_label>Premixed insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Patients with age between 18 and 70 years.&#xD;
&#xD;
          -  Hemoglobin A1c&gt;7.5%, and ≤11%.&#xD;
&#xD;
          -  Fasting plasma glucose &gt;7 mmol/L.&#xD;
&#xD;
          -  Fasting C peptide &gt;1 ng/mL.&#xD;
&#xD;
          -  Type 2 diabetes (T2DM) patients with diabetes diagnosis between 2 and 10 years (World&#xD;
             Health Organization 1999 T2DM diagnose criteria).&#xD;
&#xD;
          -  Continuous treatment with stable doses of metformin (≥1 g/day) and 1 oral&#xD;
             antihyperglycemic drug (at least half maximum dose) for more than 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Body mass index ≥21 kg/m2, and &lt;40 kg/m2.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  More than 7 consecutive days of insulin treatment within the 12 months except for&#xD;
             acute disease or surgery.&#xD;
&#xD;
          -  Diabetes other than T2DM (e.g. type 1 diabetes, diabetes secondary to pancreatic&#xD;
             disorders, drug or chemical agent intake).&#xD;
&#xD;
          -  History of hypoglycemia unawareness or recurrent hypoglycemia or severe hypoglycemia&#xD;
             within the past 12 months.&#xD;
&#xD;
          -  History of sensitivity to the study drugs or to drugs with a similar chemical&#xD;
             structure.&#xD;
&#xD;
          -  Pregnancy or planned pregnancy or current lactation (women of childbearing potential&#xD;
             must have a negative pregnancy test at study entry and a medically approved&#xD;
             contraception method).&#xD;
&#xD;
          -  Acute diabetic complications (diabetic ketoacidosis, lactic acidosis, hyperosmolar&#xD;
             nonketotic diabetic coma) within the past 12 months.&#xD;
&#xD;
          -  Significant diabetic complications and serious disease, e.g., symptomatic autonomic&#xD;
             neuropathy, gastroparesis, unstable angina or active proliferative retinopathy.&#xD;
&#xD;
          -  Acute infections which may affect BG control within the past 4 weeks.&#xD;
&#xD;
          -  Active liver disease, alanine transaminase (ALT) and/or aspartate aminotransferase&#xD;
             (AST) greater than two times the upper limit of the reference range at screening.&#xD;
&#xD;
          -  Impaired renal function, defined as but not limited to, serum creatinine levels ≥1.5&#xD;
             mg/dL (132 μmol/L) for males and ≥1.4 mg/dL (123 μmol/L) for females or presence of&#xD;
             macroproteinuria (&gt;2 g/day).&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHINA</name>
      <address>
        <city>China</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2017</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Acarbose</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Repaglinide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

